Linscomb & Williams Inc. cut its stake in shares of Shire PLC (NASDAQ:SHPG) by 4.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,283 shares of the biopharmaceutical company’s stock after selling 60 shares during the period. Linscomb & Williams Inc.’s holdings in Shire PLC were worth $212,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Maverick Capital Ltd. increased its holdings in shares of Shire PLC by 19.9% during the second quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock worth $320,969,000 after buying an additional 322,610 shares in the last quarter. Glenview Capital Management LLC increased its holdings in shares of Shire PLC by 69.7% during the second quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock worth $284,756,000 after buying an additional 707,500 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Shire PLC by 0.9% during the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after buying an additional 13,665 shares in the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Shire PLC by 14.7% during the second quarter. Ameriprise Financial Inc. now owns 1,510,227 shares of the biopharmaceutical company’s stock worth $249,577,000 after buying an additional 194,059 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in shares of Shire PLC by 4,217.7% during the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after buying an additional 1,400,275 shares in the last quarter. Institutional investors own 19.28% of the company’s stock.

Shares of Shire PLC (SHPG) traded up 0.75% during mid-day trading on Friday, reaching $153.42. 269,107 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $153.21 and a 200-day moving average price of $165.31. Shire PLC has a one year low of $139.36 and a one year high of $194.60. The stock has a market cap of $45.70 billion, a PE ratio of 68.64 and a beta of 1.63.

Shire PLC (NASDAQ:SHPG) last released its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. On average, analysts predict that Shire PLC will post $14.93 EPS for the current year.

The company also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 8th will be given a $0.1527 dividend. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s payout ratio is 41.07%.

Several brokerages have recently issued reports on SHPG. Royal Bank Of Canada reiterated an “outperform” rating and set a $213.00 price target on shares of Shire PLC in a report on Wednesday. Stifel Nicolaus reiterated a “buy” rating and set a $245.00 price target on shares of Shire PLC in a report on Sunday, October 8th. Cantor Fitzgerald reiterated a “buy” rating and set a $222.00 price target on shares of Shire PLC in a report on Thursday, September 14th. ValuEngine downgraded shares of Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Finally, Evercore ISI began coverage on shares of Shire PLC in a report on Wednesday, August 16th. They set an “outperform” rating and a $196.00 price target for the company. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and thirteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $220.91.

COPYRIGHT VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/10/13/shire-plc-shpg-shares-sold-by-linscomb-williams-inc.html.

Shire PLC Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.